2025-08-14 - Analysis Report
Okay, here's a report analyzing Eli Lilly and Co (LLY), incorporating the provided data and analysis requests.

## Eli Lilly and Co (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

*   **Ticker:** LLY
*   **Cumulative Return (LLY):** 194.06%
*   **Cumulative Return (VOO):** 86.23%
*   **Absolute Divergence:** 116.8
*   **Divergence Range:** (Min: -15.2, Max: 326.2)
*   **Relative Divergence:** 38.7

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO).  The absolute divergence of 116.8 indicates a substantial difference in cumulative returns. A relative divergence of 38.7 suggests that the current divergence, while positive for LLY, is not at its historical maximum.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta | Cap(B) |
|------------|---------|---------|---------|------|--------|
| 2015-2017  | 1.0%    | 0.0%    | -2.0%   | -0.1 | 75.7   |
| 2016-2018  | 27.0%   | 58.6%   | 32.0%   | 0.0  | 103.7  |
| 2017-2019  | 41.0%   | 58.6%   | 18.0%   | 0.0  | 117.8  |
| 2018-2020  | 53.0%   | 58.6%   | 26.0%   | 0.0  | 151.4  |
| 2019-2021  | 104.0%  | 60.6%   | 55.0%   | 0.0  | 247.6  |
| 2020-2022  | 96.0%   | 65.0%   | 89.0%   | 0.1  | 328.0  |
| 2021-2023  | 129.0%  | 65.0%   | 109.0%  | 0.2  | 522.6  |
| 2022-2024  | 145.0%  | 72.0%   | 119.0%  | 0.2  | 692.1  |
| 2023-2025  | 57.0%   | 76.8%   | 6.0%    | 0.2  | 592.1  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  CAGR shows strong growth, particularly in recent periods (2019-2024).  The last period has dropped significantly.
*   **MDD (Maximum Drawdown):** The MDD increased over the periods, indicating higher potential downside risk.
*   **Alpha:** Consistently high positive alpha values demonstrate significant outperformance compared to the market risk-adjusted return.
*   **Beta:** The Beta is low, suggesting low correlation with the market.
*   **Cap(B):** Market capitalization has grown substantially.

### 2. Recent Price Action

*   **Current Price:** 660.49
*   **Previous Close:** 639.43
*   **Change:** 3.29
*   **5-Day Moving Average:** 640.33
*   **20-Day Moving Average:** 740.2675
*   **60-Day Moving Average:** 760.8283

**Analysis:** The price increased significantly compared to the previous close, which could be due to news or events.  The current price is below the 20-day and 60-day moving averages, suggesting a potential short-term downtrend or pullback.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3234 (Low Risk)
*   **RSI:** 24.75 (Oversold)
*   **PPO:** -1.96
*   **Hybrid Signal:** cash_69%_Sell 0.6% of holdings (1 shares - Caution - MRI:0.34) (Cash Ratio: 69% on 2025-08-04)
*   **Recent Change in Relative Divergence (20-day):** -6.7 (Negative - Short-term Decrease)
*   **Expected Return (%):** 268.7%

**Analysis:**

*   **MRI:** Indicates a low-risk market environment for the stock.
*   **RSI:** The RSI suggests the stock is oversold, potentially indicating a buying opportunity.
*   **PPO:** A negative PPO suggests a downward trend in price momentum.
*   **Hybrid Signal:** The signal suggests caution and suggests selling a very small portion of holdings.
*   **Recent Change in Relative Divergence:** The recent decrease in relative divergence confirms the recent price weakness compared to the S&P 500.
*   **Expected Return:** The very high expected return suggests strong future growth potential compared to the S&P 500 over a longer investment horizon (2+ years) for dollar-cost averaging strategy.

### 4. Recent News & Significant Events

*   **[2025-08-14]:** Major business developments, regulatory changes, or market events.
*   **[2025-08-10]:** Analyst discussions on recent performance and outlook.
*   **[2025-08-11]:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **[2025-08-13]:** Market experts highlighting risks and opportunities, advising investors to monitor news and announcements.

**Analysis:** Recent news suggests increased volatility and significant developments impacting LLY. Investors should closely monitor company announcements and analyst reports.

### 5. Recent Earnings Analysis

| 날짜         | EPS  | 매출           |
|--------------|------|----------------|
| 2025-08-07   | 6.3  | 15.56 B$      |
| 2025-05-01   | 3.07 | 12.73 B$      |
| 2024-10-30   | 1.08 | 11.44 B$      |
| 2024-08-08   | 3.29 | 11.30 B$      |
| 2025-08-07   | 3.29 | 11.30 B$      |

**Analysis:**

*   Earnings Per Share (EPS) and revenue have generally increased over the reported quarters.
*   The latest EPS (6.3) and revenue (15.56 B$) indicate strong performance.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | $15.56B    | 84.27%        |
| 2025-03-31 | $12.73B    | 82.53%        |
| 2024-12-31 | $13.53B    | 82.24%        |
| 2024-09-30 | $11.44B    | 81.02%        |
| 2024-06-30 | $11.30B    | 80.80%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE       |
|------------|------------|-----------|
| 2025-06-30 | $18.27B    | 30.98%    |
| 2025-03-31 | $15.76B    | 17.50%    |
| 2024-12-31 | $14.19B    | 31.07%    |
| 2024-09-30 | $14.24B    | 6.81%     |
| 2024-06-30 | $13.56B    | 21.88%    |

**Analysis:**

*   **Revenue and Profitability:** Both revenue and profit margins have consistently increased. The profit margins are very high, indicating strong profitability.
*   **Capital and Profitability:** Equity has grown, and ROE (Return on Equity) is volatile but generally strong, indicating efficient use of shareholder equity.

### 7. Overall Summary and Recommendation

Eli Lilly and Co (LLY) demonstrates strong financial performance, including substantial revenue growth, high-profit margins, and significant outperformance compared to the S&P 500. Recent earnings and revenue data confirm this positive trend.

**Key Positives:**

*   Strong cumulative return and high alpha values indicate significant outperformance.
*   Recent EPS and revenue growth are positive indicators.
*   High-profit margins and robust ROE highlight efficient capital management.
*   Long-term growth potential based on expected return.

**Key Considerations:**

*   Recent price volatility and the negative change in relative divergence suggest short-term weakness.
*   The stock is currently below its 20-day and 60-day moving averages, indicating a potential short-term downtrend.
*   High MDD values suggest that there is significant downside risk.
*   Recent news indicates increased volatility and important company developments.

**Recommendation:**

Based on the analysis, a mixed approach is warranted.

*   **Long-Term Investors:** The high expected return and strong financial performance suggest that LLY is a promising long-term investment, particularly suitable for dollar-cost averaging (gradual investment over time) to mitigate volatility.
*   **Short-Term Investors:** Exercise caution due to recent price weakness and volatility. Monitor news and company announcements closely before making any short-term trading decisions. The oversold RSI might present a buying opportunity, but confirmation from other indicators is recommended.
